Clinical Trials Logo

Carcinoma, Renal Cell (Advanced) clinical trials

View clinical trials related to Carcinoma, Renal Cell (Advanced).

Filter by:
  • None
  • Page 1

NCT ID: NCT00895674 Completed - Clinical trials for Carcinoma, Renal Cell

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Start date: July 2006
Phase: N/A
Study type: Observational

Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis. When this study has been started the standard therapy for patients has been cytokines, which might be accompanied by significant toxicities or might fail the therapeutic goal. In these cases sorafenib can be a feasible therapeutic option. This non-interventional study has been created and is being conducted to collect clinical data on the patients' therapy with sorafenib in an everyday treatment schedule. The main goal of this study focuses on patient characteristics and tumor status in RCC treated with sorafenib as well as the treatment duration and safety of sorafenib under everyday treatment conditions.

NCT ID: NCT00771147 Completed - Clinical trials for Carcinoma, Renal Cell

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®

PONDIAC
Start date: June 2008
Phase: N/A
Study type: Observational

Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.

NCT ID: NCT00700258 Completed - Clinical trials for Lymphoma, Mantle-Cell

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

STAR-TOR
Start date: February 13, 2008
Phase:
Study type: Observational

The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use